CRISPR THERAPEUTICS AG APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CRISPR THERAPEUTICS AG (CRSP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $17.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $17.32M, a 1.65% decline year-over-year.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $16.32M, a 19.24% decline year-over-year.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $16.60M, a 22.93% decline year-over-year.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $17.61M, a 25.62% decline year-over-year.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $72.50M, a 16.25% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $86.57M, a 6.84% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $81.03M, a 17.27% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $97.95M, a 4.34% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.32M 10-Q · filed 2026-08-03 | $33.64M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $16.32M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $72.50M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $16.60M 10-Q · filed 2025-11-10 | $34.21M derived: sum of 2 quarters · filed 2026-08-03 | $54.42M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | $17.61M 10-Q · filed 2026-08-03 | $37.82M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $20.21M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $86.57M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $21.54M 10-Q · filed 2025-11-10 | $45.22M derived: sum of 2 quarters · filed 2025-11-10 | $64.62M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $23.67M 10-Q · filed 2025-11-10 | $43.08M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $19.41M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $81.03M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $19.97M 10-Q · filed 2024-11-05 | $41.73M derived: sum of 2 quarters · filed 2024-11-05 | $62.61M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $21.77M 10-Q · filed 2024-11-05 | $42.64M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $20.88M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $97.95M 10-K · filed 2025-02-11 | |||
| 2022-09-30 | $24.54M 10-Q · filed 2023-11-06 | $49.40M derived: sum of 2 quarters · filed 2023-11-06 | $75.14M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $24.85M 10-Q · filed 2023-11-06 | $50.60M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $25.75M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $102.39M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $26.20M 10-Q · filed 2022-11-01 | $54.53M derived: sum of 2 quarters · filed 2022-11-01 | $76.62M derived: sum of 3 quarters · filed 2022-11-01 | |
| 2021-06-30 | $28.33M 10-Q · filed 2022-11-01 | $50.42M derived: sum of 2 quarters · filed 2022-11-01 | ||
| 2021-03-31 | $22.09M 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $66.02M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $17.24M 10-Q · filed 2021-11-03 | $32.94M derived: sum of 2 quarters · filed 2021-11-03 | $47.09M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $15.70M 10-Q · filed 2021-11-03 | $29.85M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $14.15M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $49.52M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $14.77M 10-Q · filed 2020-10-28 | $26.97M derived: sum of 2 quarters · filed 2020-10-28 | $37.67M derived: sum of 3 quarters · filed 2020-10-28 | |
| 2019-06-30 | $12.20M 10-Q · filed 2020-10-28 | $22.89M derived: sum of 2 quarters · filed 2020-10-28 | ||
| 2019-03-31 | $10.70M 10-Q · filed 2020-10-28 | |||
| 2018-12-31 | $39.26M 10-K · filed 2021-02-16 | |||
| 2018-09-30 | $9.07M 10-Q · filed 2019-10-28 | $18.54M derived: sum of 2 quarters · filed 2019-10-28 | $25.22M derived: sum of 3 quarters · filed 2019-10-28 | |
| 2018-06-30 | $9.48M 10-Q · filed 2019-10-28 | $16.15M derived: sum of 2 quarters · filed 2019-10-28 | ||
| 2018-03-31 | $6.67M 10-Q · filed 2019-10-28 | |||
| 2017-12-31 | $20.64M 10-K · filed 2020-02-12 | |||
| 2016-12-31 | $10.84M 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $3.68M 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $695.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |